Skip to main content
See All Clinical Research Trials

AMG 510 (pINN) Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) (Amgen 20190135 Subprotocol E)

A Phase 1b, Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 (pINN) Sotorasib Monotherapy and in Combination With Other Anti-cancer Therapies in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation

To evaluate the safety and tolerability of sotorasib administered in investigational regimens in adult subjects with KRAS p.G12C mutant advanced solid tumors.

Closed
Learn More

To learn more, visit ClinicalTrials.Gov or contact Clinical Research at 864-560-6812.

Sponsor(s)

Amgen

Key Trial Criteria